Investigation of theIn VitroActivity of Streptomycin AgainstMycobacterium tuberculosis
Autor: | Pilar Ruiz, M. Casal, F.J. Zerolo, F. Rodríguez-Cano |
---|---|
Rok vydání: | 2002 |
Předmět: |
Microbiology (medical)
Tuberculosis medicine.drug_class Immunology Antibiotics Microbial Sensitivity Tests Drug resistance Biology Microbiology Bacterial genetics Mycobacterium tuberculosis medicine Antibiotics Antitubercular Lung Ethambutol Pharmacology Isoniazid Drug Resistance Microbial biochemical phenomena metabolism and nutrition biology.organism_classification medicine.disease Virology Drug Resistance Multiple DNA-Binding Proteins RNA Bacterial RNA Ribosomal Spain Streptomycin Transcription Factors medicine.drug |
Zdroj: | Microbial Drug Resistance. 8:147-149 |
ISSN: | 1931-8448 1076-6294 |
DOI: | 10.1089/107662902760190707 |
Popis: | Streptomycin was the first antibiotic used against Mycobacterium tuberculosis. It was used for years in monotherapy regimens, leading to the emergence of resistance; therefore, its use gradually waned. Given the resistance rates detected with current antituberculosis drugs, the use of streptomycin has gained renewed interest. The mechanism of action of streptomycin is inhibition of protein synthesis of mycobacteria in the ribosome. Resistance emerges when mutations appear in genes encoding 16S rRNA and protein S12. The activity of streptomycin against 1,496 M. tuberculosis strains was investigated; 1,186 and 196 strains corresponded to pulmonary and extrapulmonary specimens, respectively. For 114 strains, the source was not indicated. Initially, the BACTEC 460 TB system was used for antibiotic susceptibility testing. Since 1996, the ESP II system was used. The strains ATCC27294 (sensitive to streptomycin, rifampin, ethambutol, and isoniazid) and ATCC35820 (resistant to streptomycin) were used as controls. An overall resistance rate of 2.2% was obtained. In all cases secondary resistance was observed. Multiresistance was observed in 23 strains. |
Databáze: | OpenAIRE |
Externí odkaz: |